9 completed, 8 terminated, 5 withdrawn, 2 unknown. 25 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 9, Terminated 8, Withdrawn 5, Unknown 2, Active not recruiting 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Pituitary Neoplasms: new trials by email Literature Review of Pituitary Neoplasms trials Research Report on Pituitary Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery Tranexamic acid, Placebo - Pituitary Tumor, Blood Loss | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2022-03-01 | 2022-04-05 | |
| TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas TBR-760, Placebo - Non-Functional Pituitary Adenoma, Pituitary Tumor, Nonfunctioning | Phase 2 | Unknown | Tiburio Therapeutics | 150 | 2020-05-01 | 2020-04-06 |
| The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas Radiotherapy plus temozolomide, Radiotherapy plus placebo - Pituitary Adenomas | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 150 | 2020-02-10 | 2020-01-28 |
| Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors Ipilimumab, Nivolumab - Pituitary, Pituitary Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 10 | 2019-07-31 | 2026-06-02 |
| Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers Lutetium Lu 177 Dotatate - Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-06-13 | 2020-09-07 | |
| Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas Capecitabine, Temozolomide - Recurrent Pituitary Adenomas | Phase 2 | Terminated | Weill Medical College of Cornell University | 1 | 2019-05-21 | 2022-08-09 |
| Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Pasireotide LAR - Pituitary Tumor, ACTH-producing Pituitary Tumour | Phase 2 | Terminated | Columbia University | 4 | 2017-07-10 | 2021-04-27 |
| Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Ropinirole - Hyperprolactinemia, Prolactinoma | Phase 1 / Phase 2 | Completed | Columbia University | 16 | 2016-09-16 | 2024-06-04 |
| Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Photofrin photodynamic therapy. - Brain Tumor, Recurrent | Phase 2 | Terminated | Harry T Whelan, MD | 1 | 2015-06-01 | 2019-08-20 |
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Pasireotide with or without cabergoline - Cushings Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 68 | 2014-03-06 | 2020-09-18 |
| Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy Radiation according to indication with hippocampal sparing, Radiation according to indication without hippocampal protection - Radiation of Neurocranial Region | Phase 2 | Active not recruiting | University of Erlangen-Nürnberg Medical School | 150 | 2013-03-01 | 2026-10-27 |
| Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism Pasireotide LAR - Acromegaly, Pituitary Gigantism | Phase 2 | Completed | Novartis Pharmaceuticals | 33 | 2012-10-16 | 2019-09-16 |
| Pasireotide Therapy in Patients With Nelson's Syndrome Pasireotide - Nelson Syndrome | Phase 2 | Terminated | Sheffield Teaching Hospitals NHS Foundation Trust | 8 | 2011-03-01 | 2016-11-02 |
| Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Farletuzumab - Resectable, Non-functioning Pituitary Adenoma | Phase 2 | Withdrawn | Morphotek | 2011-02-01 | 2013-11-04 | |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Pasireotide, cabergoline - Non-functioning Pituitary Adenomas, Prolactinomas | Phase 2 / Phase 3 | Completed | Universidade Federal do Rio de Janeiro | 21 | 2010-03-01 | 2016-08-22 |
| Temozolomide in Treating Patients With Invasive Pituitary Tumors temozolomide, DNA methylation analysis, microarray analysis - Brain and Central Nervous System Tumors | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2009-12-01 | 2020-07-31 | |
| Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin pasireotide LAR - Pancreatic Neoplasm, Pituitary Neoplasm | Phase 2 | Terminated | Novartis Pharmaceuticals | 118 | 2009-09-01 | 2016-07-26 |
| Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Lapatinib - Pituitary Adenomas, Prolactinomas | Phase 2 | Completed | Cedars-Sinai Medical Center | 9 | 2009-07-01 | 2020-01-22 |
| Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas pasireotide LAR - Gonadotroph Adenomas | Phase 2 | Terminated | University of Pennsylvania | 2 | 2009-06-01 | 2017-11-28 |
| Rosiglitazone in Treating Patients With Pituitary Tumors rosiglitazone maleate - Brain and Central Nervous System Tumors | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 1 | 2006-10-01 | 2020-08-14 |
Showing 20 of 25. Sign in to see all of them.
Prolactinoma (5) · Acromegaly (2) · Brain Neoplasms (2) · Central Nervous System Neoplasms (2) · Growth Hormone-Secreting Pituitary Adenoma (2) · Meningioma (2) · Nelson Syndrome (2) · Pituitary Diseases (2) · ACTH Syndrome, Ectopic (1) · Adenoma, Acidophil (1) · Adenoma, Basophil (1) · Adenoma, Chromophobe (1) · Adrenocortical Hyperfunction (1) · Astrocytoma (1)
Brain Diseases (25) · Central Nervous System Diseases (25) · Endocrine Gland Neoplasms (25) · Endocrine System Diseases (25) · Hypothalamic Diseases (25) · Neoplasms (25) · Neoplasms by Site (25) · Nervous System Diseases (25) · Pituitary Diseases (23) · Hypothalamic Neoplasms (21) · Nervous System Neoplasms (21) · Supratentorial Neoplasms (21) · Brain Neoplasms (19) · Central Nervous System Neoplasms (19) · Neoplasms by Histologic Type (10)
pasireotide (6) · Temozolomide (3) · Cabergoline (2) · Biological Therapy (1) · Capecitabine (1) · Clomiphene (1) · Complementary Therapies (1) · DNA Methylation (1) · Ipilimumab (1) · Lapatinib (1) · Microarray Analysis (1) · Nivolumab (1) · Radiotherapy (1) · Rosiglitazone (1) · TBR-760 (1)
Novartis Pharmaceuticals (3) · Columbia University (2) · Jonsson Comprehensive Cancer Center (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Burzynski Research Institute (1) · Cedars-Sinai Medical Center (1) · Endocyte (1) · Federal University of São Paulo (1) · Harry T Whelan, MD (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Morphotek (1) · Peking Union Medical College Hospital (1) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · Tiburio Therapeutics (1)
United States (16) · Brazil (4) · Germany (3) · Argentina (2) · France (2) · Italy (2) · Mexico (2) · Spain (2) · Australia (1) · Belgium (1) · Canada (1) · Colombia (1) · Greece (1) · Hungary (1) · India (1)
Anthony Heaney, MD (2) · Andrew Lin, MD (1) · Brent Senior, MD (1) · Bruce Wallin, MD (1) · Camilo Jimenez (1) · Gabrielle Page-Wilson, M.D. (1) · Harry T Whelan, MD (1) · Joanna Klubo-Gwiezdzinska, M.D. (1) · John Newell-Price (1) · Julio Abucham, MD, PhD (1) · Nelson Oyesiku, MD (1) · Nelson Oyesiku, MD, PhD, FACS (1) · Odelia Cooper, MD (1)
PMID 29313180, PMID 33150390, PMID 33362722, PMID 35954244, PMID 36856733, PMID 37715962, PMID 37876540
2008 (1), 2009 (1), R21DK112093 (1)